Clinical Trials
66 trialsNCT05714839 2026-05-22
DREAMM-20
GlaxoSmithKline
Phase 1/2 Recruiting
NCT05853965 2026-05-18
BELI(E)VE
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2 Recruiting
NCT07116616 2026-05-18
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ModernaTX, Inc.
Phase 1/2 Recruiting
NCT07479979 2026-05-14
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
Hoosier Cancer Research Network
Phase 1/2 Recruiting
NCT05828511 2026-05-13
LINKER-MM4
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT04973605 2026-05-11
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
Phase 1/2 Recruiting
NCT05092451 2026-05-06
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT05850234 2026-05-06
DURGA-1
AstraZeneca
Phase 1/2 Recruiting
NCT06106945 2026-05-06
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
AstraZeneca
Phase 1/2 Recruiting
NCT05583617 2026-05-04
PLYCOM
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT06292780 2026-04-29
LINKER-AL2
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT06429150 2026-04-24
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Recruiting
NCT03761108 2026-04-20
LINKER-MM1
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT07455851 2026-04-15
A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT06669247 2026-04-13
COSTIMM
Regeneron Pharmaceuticals
Phase 1/2 Recruiting
NCT07523555 2026-04-13
ADAPT-HEM
Beijing Biotech
Phase 1/2 Recruiting
NCT06536413 2026-04-03
ATRA
The Methodist Hospital Research Institute
Phase 1/2 Recruiting
NCT07181941 2026-03-27
Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma
Fred Hutchinson Cancer Center
Phase 1/2 Recruiting
NCT06232044 2026-03-25
Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma
Alliance for Clinical Trials in Oncology
Phase 1/2 Recruiting
NCT04988555 2026-03-24
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
NCT07477912 2026-03-17
MSTH-CAR001
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology
Phase 1/2 Recruiting
NCT07169500 2026-03-02
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Recruiting
NCT06235229 2026-02-25
DURGA-3
Gracell Biotechnologies (Shanghai) Co., Ltd.
Phase 1/2 Recruiting
NCT06953960 2026-02-23
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
AbbVie
Phase 1/2 Recruiting
NCT05199311 2026-02-18
Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Transplant Eligible Multiple Myeloma
Hackensack Meridian Health
Phase 1/2 Recruiting
NCT06105554 2026-02-18
Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1/2 Recruiting
NCT07410494 2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2 Recruiting
NCT06892522 2026-02-17
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
AbbVie
Phase 1/2 Recruiting
NCT07099391 2026-02-11
A Study of Dara-RVd and Teclistamab-RVd in People With Multiple Myeloma
Memorial Sloan Kettering Cancer Center
Phase 1/2 Recruiting
NCT06988488 2026-02-02
A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
Celgene
Phase 1/2 Recruiting
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT06518551 2025-12-11
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT06049290 2025-12-04
A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2 Recruiting
NCT06645678 2025-12-03
MELT-MM
Seoul National University Hospital
Phase 1/2 Recruiting
NCT05632380 2025-10-01
ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)
Institute of Hematology & Blood Diseases Hospital, China
Phase 1/2 Recruiting
NCT06785415 2025-09-30
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Mayo Clinic
Phase 1/2 Recruiting
NCT06572605 2025-09-19
External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease
City of Hope Medical Center
Phase 1/2 Recruiting
NCT05372354 2025-09-05
A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT06616389 2025-08-19
Study of ODX (OsteoDex) in Multiple Myeloma
DexTech Medical AB
Phase 1/2 Recruiting
NCT05565807 2025-08-15
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Zhejiang ACEA Pharmaceutical Co. Ltd.
Phase 1/2 Recruiting
NCT05841550 2025-08-05
The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma
Oslo University Hospital
Phase 1/2 Recruiting
NCT07032129 2025-06-22
BAH2573
Essen Biotech
Phase 1/2 Recruiting
NCT06087653 2025-06-19
Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)
Starton Therapeutics, Inc
Phase 1/2 Recruiting
NCT06119685 2025-06-03
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Indapta Therapeutics, INC.
Phase 1/2 Recruiting
NCT05908409 2025-05-01
CASSANDRA
IDP Discovery Pharma S.L.
Phase 1/2 Recruiting
NCT06911710 2025-04-04
CAR-T
Tianjin Medical University General Hospital
Phase 1/2 Recruiting
NCT06484829 2025-04-02
Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Chengdu Zenitar Biomedical Technology Co., Ltd
Phase 1/2 Recruiting
NCT04271644 2025-02-25
BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Recruiting
NCT04776330 2025-02-25
a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Chongqing Precision Biotech Co., Ltd
Phase 1/2 Recruiting
NCT06759181 2025-01-06
Safety and Efficacy of Anti-BCMA/FcRL5 CAR-T Cell Therapy in Treating Relapsed and Refractory Multiple Myeloma (R/R MM)
Xuzhou Medical University
Phase 1/2 Recruiting